Jeffrey M.  Fryer net worth and biography

Jeffrey Fryer Biography and Net Worth

Insider of Rallybio
Jeff is a Co-Founder and Chief Financial Officer of Rallybio and has more than 30 years of experience in accounting, finance, economics, corporate strategy and taxation. He has held leadership roles at Alexion Pharmaceuticals, Chemtura Corporation, and Lydall, and began his career in public accounting with PricewaterhouseCoopers.

He earned a B.S. in business administration with a concentration in accounting from Bryant University and a Master of Science in taxation from the University of Hartford. He is a member of the Dean’s Advisory Council for the Bryant University School of Business.

OTHER THINGS WORTH KNOWING ABOUT ME:

My dream vacation is a trip to the International Space Station.

When I’m not working, I’m never sitting still. I enjoy biking, boating, scuba diving, skiing, snowmobiling, photography, and even some acting now and then – maybe you’ve seen me on TV!

My greatest non-work accomplishment is being a dad to two amazing guys and our puppy, who make me smile every day.

How do I contact Jeffrey M. Fryer?

The corporate mailing address for Mr. Fryer and other Rallybio executives is , , . Rallybio can also be reached via phone at 203-59-3820 and via email at [email protected]. Learn More on Jeffrey M. Fryer's contact information.

Has Jeffrey M. Fryer been buying or selling shares of Rallybio?

Jeffrey M. Fryer has not been actively trading shares of Rallybio during the last quarter. Most recently, on Monday, March 21st, Jeffrey M. Fryer bought 3,000 shares of Rallybio stock. The stock was acquired at an average cost of $8.04 per share, with a total value of $24,120.00. Learn More on Jeffrey M. Fryer's trading history.

Who are Rallybio's active insiders?

Rallybio's insider roster includes Jeffrey Fryer (Insider), Martin Mackay (CEO), and Stephen Uden (Insider). Learn More on Rallybio's active insiders.

Jeffrey M. Fryer Insider Trading History at Rallybio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/21/2022Buy3,000$8.04$24,120.00View SEC Filing Icon  
1/19/2022Buy1,400$8.70$12,180.00View SEC Filing Icon  
1/7/2022Buy10,000$9.41$94,100.00View SEC Filing Icon  
See Full Table

Jeffrey M. Fryer Buying and Selling Activity at Rallybio

This chart shows Jeffrey M Fryer's buying and selling at Rallybio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rallybio Company Overview

Rallybio logo
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $0.98
Low: $0.98
High: $1.04

50 Day Range

MA: $1.07
Low: $0.96
High: $1.17

2 Week Range

Now: $0.98
Low: $0.95
High: $3.46

Volume

8,441 shs

Average Volume

559,662 shs

Market Capitalization

$40.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A